Discover Algeria | Press area | Contact  
English Français
Registration
English Français

December 17, 2023 | 2 years ago

  • More options

    Share on LinkedIn
    Share on Twitter

Saïdal's business model to reduce the drugs import bill by 1.1 billion dollars by 2026

Saïdal's business model to reduce the drugs import bill by 1.1 billion dollars by 2026

news-detail

In a statement to APS on the sidelines of the laying of the foundation stone for the construction of two new factories in the province of Mostaganem, Mr Kouidri said that Saïdal was moving towards a new business model, working on the manufacture of raw materials used in the production of certain medicines, which would reduce the import bill by 1.1 billion dollars by 2026.


With regard to the Saïdal Group's ninth site in the province of Mostaganem, the same official said that this project was a complement to Saïdal's products, which are currently in short supply, namely veterinary and ophthalmic medicines, which are also part of the objectives of the new business model.

With regard to the production of veterinary medicines, he said that this project was part of the country's approach to national health security, bearing in mind that over 80% of the medicines to be produced by the Mostaganem plant are currently imported in foreign currency, at a cost of between 110 and 120 million dollars a year.

Through its eight production sites, the Saïdal Group currently manufactures 160 medicines, covering 20 therapeutic classes, with an estimated annual production capacity of 220 million sales units, he added.


December 18, 2023 | algeria-logo

  • More options

    Share on LinkedIn
    Share on Twitter
Subscribe to the economic newsletter